MORBO DI CROHN: ANTAGONISTI IL-23p19 VS USTEKINUMAB. UN’OTTIMA META-ANALISI SUI 5 TRIAL DI CONFRONTO DIRETTO. DA “Am J Gastroenterol”
IL-23p19 Antagonists vs Ustekinumab for Treatment of Crohn’s Disease: A Meta-Analysis of Randomized Controlled Trials Claudia Dziegielewsk et al. Abstract…

